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Abstract: Focal adhesion kinase (FAK) and steroid receptor coactivator (Src) are intracellular
(nonreceptor) tyrosine kinases that physically and functionally interact to promote a variety of
cellular responses. Plenty of reports have already suggested an additional central role for this
complex in cancer through its ability to promote proliferation and anoikis resistance in tumor
cells. An important role for the FAK/Src complex in tumor angiogenesis has also been established.
Furthermore, FAK and Src have been associated with solid tumor metastasis through their
ability to promote the epithelial mesenchymal transition. In fact, a strong correlation between
increased FAK/Src expression/phosphorylation and the invasive phenotype in human tumors has
been found. Additionally, an association for FAK/Src with resistances to the current anticancer
therapies has already been established. Currently, novel anticancer agents that target FAK or
Src are under development in a broad variety of solid tumors. In this article we will review the
normal cellular functions of the FAK/Src complex as an effector of integrin and/or tyrosine kinase
receptor signaling. We will also collect data about their role in cancer and we will summarize the
most recent data from the FAK and Src inhibitors under clinical and preclinical development.
Furthermore, the association of both these proteins with chemotherapy and hormonal therapy
resistances, as a rationale for new combined therapeutic approaches with these novel agents, to
abrogate treatment associated resistances, will also be reviewed.
Keywords: SRC, FAK, cancer, therapeutic target, FAK inhibitors, SRC inhibitors

Integrins are a family of transmembrane receptors that link the extracellular matrix
(ECM) and the intracellular actin-cytoskeleton. These cell-matrix areas of adhesion are
known as focal adhesion (FA) contacts/areas. Integrins cluster when they bind to ECM.
Integrin clustering has a structural role but also induces the activation of intracellular
signaling pathways that lead to important cellular responses such as proliferation,
survival, migration and invasion in both normal and tumor cells.1 In this setting, the
linked activities of two nonreceptor intracellular tyrosine kinases, focal adhesion kinase
(FAK) and steroid receptor coactivator (Src), is a common intracellular point of convergence in the signaling initiated by this integrin-ECM interaction. In response to the
clustering, FAK associates to the cytoplasmic tail of the integrin and in response to this
association FAK phosphorylates at its tyrosine residue 397 (Y397). Although this Y397
phosphorylation is mainly due to autophosphorylation; transphosphorylation by growth
factors might also occur. This phosphorylated tyrosine provides a docking site for Src
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(Figure 1).2 The tyrosine kinase Src, then, phosphorylates
additional sites on FAK, leading to further increased activity
of FAK and allowing the recruitment of proteins that contain
Src homology 2 (SH2) domains such as Grb2 and PI3K.3
The mutually activated FAK/Src complex then initiates a
cascade of phosphorylation events of new protein–protein
interactions to trigger several signaling pathways that
eventually leads to different cellular responses. For instance,
Grb2, once bound to FAK can recruit SOS into the complex
and activates the downstream Ras-MAPK pathway and/or
may also transduces the signal through the activation of the
PI3K-Akt cascade.3–5
Adhesion is a hallmark of solid cancer cells and integrins
are a nexus between intracellular signaling and cytoskeletal
dynamics; besides, integrin-mediated signaling also intersects
with growth factor-mediated signaling through various levels
of cross-talk. In this complex network, the FAK/Src complex
also transduces signals from tyrosine kinase receptors (TKRs)
or integrates signals from both, integrins and TKRs, (see
Figure 1) in normal and tumor cells.3,4 As an illustration of
this connection in breast cancer, transforming growth factor
β (TGF-β) has recently been found to be able to induce
membrane-proximal clustering of human EGF (Epidermal
Growth Factor) receptor 2, (HER2) and integrins by activating
Src-FAK and receptor association to the cytoskeleton.6
Platelet-derived growth factor receptor (PDGF-R),
epidermal growth factor receptor (EGF-R), fibroblast
growth factor receptor (FGF-R), insulin-like growth factor1 receptor (IGF-1R), hepatocyte growth factor (HGF-R),
colony-stimulating factor-1 receptor (CSF-1R) or, stem cell
factor receptor (SCF-R) are also TKRs that may transduce
their signal by FAK/Src activation. As a consequence, the
FAK/Src complex is potentially involved in different steps of
tumorogenesis and further growth and metastatic progression
of malignant tumors.7,8
The increased expression or activity of FAK and/or Src
in tumors is associated with a more invasive and aggressive phenotype and has lead to the development of Src and
FAK inhibitors as new anticancer drugs.9–12 These drugs are
able to block proliferation, survival, angiogenesis and/or
migration/invasion in preclinical tumor models13 and some
of them have already shown preliminary antitumor activity
in clinical trials with cancer patients.14–19

FAK and Src structure
c-Src was the first characterized human oncogene. In 1909
Peyton Rous identified the Rous Sarcoma’s Virus (RSV).20,21
Later, in 1958, the v-Src gene was identified as the cause
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that allowed RSV to produce the sarcoma when the virus
infected healthy chickens. The v-Src gene was taken up
by RSV and incorporated into its genome conferring the
virus the advantage of being able to stimulate uncontrolled
proliferation in host chicken cells. Finally the human
homologue of the v-Src gene, c-Src, was characterized as
the first oncogene in humans.22
c-Src is a nonreceptor tyrosine kinase. The Src family
comprises of eight members in humans (Src, Fyn, Yes, Lyn,
Lck, Hck, Blk and Fgr) with a molecular weight between
52–62 KDa.22,23 Each Src kinase family member is comprised
of six domains. A SH4 domain placed at the N-terminal tail is
involved in targeting Src to the plasmatic membrane. Adjacent
to the SH4 domain, a region that is specific to each Src family member followed by a SH3 and a SH2 domain, both of
them involved in the interaction of Src with other intracellular
proteins (Figure 2).23 Additionally, in the C-terminal tail, there
is an SH1 domain involved in adenosine tri-phosphate (ATP)
and substrate binding. This SH1 domain shows tyrosine kinase
activity. The phosphorylation in the Y419 residue of the SH1
domain is required for maximum kinase activity. Immediately
adjacent to the SH1 domain, there is another C-terminal
region that acts as a negative regulatory domain that is itself
regulated by phosphorylation. After phosphorylation of the
Y530 residue, placed in this negative regulatory domain, Src
undergoes conformational changes and becomes inactive.23
Src activation is regulated at many different levels. In response
to a signal stimuli Src translocates from the cytosol to the
membrane where it will be activated by phosphorylation, the
intracellular localization of Src is therefore one of the key
regulatory mechanisms that control Src activation.24 In addition the binding of FAK to the SH2 domain of Src relieves
its autoinhibitory interaction that leads to the activation of
Src. Once activated, Src phosphorylates FAK on a number
of additional tyrosine residues, leading to further increased
activity of FAK.2,23,25 In this sense, FAK acts as a molecular
scaffold protein to activate and recruit Src to its substrates.
FAK was first identified in the search for proteins that
where tyrosine phosphorylated in an integrin dependent
manner and also in Src transformed fibroblasts as a key
substrate of Src oncoprotein.26 It was described as a focal
adhesion-associated nonreceptor protein tyrosine kinase27,28
ubiquitously expressed and encoded by an evolutionarily
highly conserved gene.
FAK harbors a central region with kinase activity that
is flanked by a large N-terminal region that contains the
erythrocyte band four 1-ezrin-radixin-moesin (FERM) domain
and by a C-terminal region that contains the focal adhesion
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Figure 1 FAK/Src complex mediated signaling pathway.
Notes: The FAK/Src complex transduces signals from a variety of membrane receptors such as tyrosine kinase repectors and integrins through the activation of intracellular
signaling pathways such as PI3K-AKt and Ras-MAPK to reach a cellular response.
Abbreviations: ERK, extracellular signal regulated kinase; FA, focal adhesions; MEK, mitogen-activated protein; FAK, focal adhesion kinase; VEGF, vascular endothelial growth
factor; MMPs, matrix metalloproteinases.

targeting (FAT) domain. The Y397 residue, immediately adjacent to the kinase domain, is autophosphorylated in response
to the clustering of integrins. This autophosphorylation
increases the catalytic activity of FAK and creates a high
affinity binding site for the SH2 domain of Src. This
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interaction recruits and activates Src. The formation of the
complex with Src is the most critical event in FAK-associated
signaling. Src binds the Y397 residue and phosphorylates
other FAK residues including Y576 and Y577 placed on the
catalytic loop of the kinase and Y861 that are important for
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Figure 2 FAK and Src structure.
Notes: A) FAK structure. FAK harbors a central region with kinase activity that is flanked by a N-terminal region that contains the FERM domain and by a C-terminal region
that contains the FAT domain. The autophosphorylation in its Y397 residue increases its catalytic kinase activity and allows the binding of specific intracellular proteins. FAK
is phosphorylated by Src in its Y576 and Y577 residues allowing its full catalytic activity. In absence of stimulus, the FERM domain works as a negative regulator of FAK activity
through its interaction with the kinase domain preventing the phosphorylation in Y397. In response of stimuli, the FERM domain interacts with the cytoplasmic tail of the
integrins. Allowing the autophosphorylation of FAK in this tyrosine. The FAT domain, placed in the C-terminal region, mediates the co-localization of FAK with the FA areas
through the interaction of FAK with the FA associated proteins talin and paxillin. Two proline-rich domains (PR) mediate the interaction of FAK with SH3 containing proteins
such as p130 CAS. B) Src structure. Src is comprised of six domains: a SH4 involved in targeting Src to the plasmatic membrane, a region U that is specific of each Src family
member, a SH3 and a SH2 domain involved in the interaction of Src with other intracellular proteins and a SH1 domain involved in ATP and substrate binding.The phosphorylation
in Y419 residue of the SH1 domain is required for maximum kinase activity. Placed immediately adjacent to the SH1 domain there is a negative regulatory domain. After
phosphorylation of the Y530 residue, in the negative regulatory domain, Src becomes inactive.
Abbreviations: FAK, focal adhesion protein; RTK, tyrosine kinase receptor; FERM, Band 4.1 Ezrin, Radixin, Moesin; PI3K, phosphoinositide 3 kinase.

full catalytic activity of FAK. Y925 has been also identified as an important site for phosphorylation by Src, which
involves Src in induced epithelial mesenchymal transitions
(EMTs).29,30 In the absence of stimuli from integrins and/or
TKRs, the FERM domain works as a negative regulator of
FAK activity. This domain interacts with the kinase domain
preventing Y397 phosphorylation. Conversely, in response
to co-clusters of integrins and TKRs, the FERM domain
interacts with the cytoplasmic tail of the integrin allowing
FAK-autophosphorylation in this Y397 residue. The FAT
domain, placed in the C-terminal region, mediates the colocalization of FAK with the FA areas through the interaction
of FAK with the FA associated proteins talin and paxillin.
Furthermore, two proline rich domains, placed adjacent to
the FAT domain, mediate the interaction of FAK with SH3
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containing proteins such as p130CAS.9,11 The ability of FAK
to promote the activation of p130CAS depends on Src activity. Although the scaffold function of FAK to recruit Src to
its substrates is has already been well established, however
less is known regarding FAK kinase activity.
Besides integrins, the N-terminal region of FAK also
interacts with TKRs, and this interaction may be involved in
the regulation of FAK activity and in addition in cross-talks
between integrins and TKRs.31 Phosphorylation of FAK.
Y861 promotes association of FAK with the αyβ5 integrin following vascular endothelial growth factor (VEGF)
stimulation.32
Different FAK isoforms from alternative splicing have
been found: FAK, proline rich tyrosine kinase 2 (PYK2) and
FAK related nonkinase (FRNK).9 FRNK lacks the catalytic
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domain working as a FAK inhibitor competing with nontruncated endogenous FAK for the localization at FA areas.33
FAK activity is under strict regulation by a variety of
kinases and phosphatases such as glycogen synthetase kinase
3 type β (GSK3 β), tyrosine phosphatase SHP-2, serine/
threonine protein phosphatase type 1 as well as by Src.9,34,35

FAK and Src and their function
in normal and tumor cells
Although, most available articles in the literature show
FAK and Src as independent proteins, the current idea that
both proteins work as a protein complex in the cellular
signaling networks is emerging. FAK would form a binary
complex with Src family kinases which can phosphorylate
other substrates and trigger multiple intracellular signaling
pathways that would induce different cellular responses.
FAK and Src are not only critical modulators of signaling
pathways mediated by TKRs and integrins, they also respond
to stimuli from G protein-coupled receptors, cell–cell
adhesion proteins (ie, cadherins) and steroid hormone
receptors to control a variety of normal and oncogenic
cellular responses such as cell survival, proliferation and
migration/invasion.4,22,23,34,36,37
FAK-null embryos exhibit an early embryonic lethal
phenotype.38 These embryos show multiple defects, including
a disorganized cardiovascular system due to extensive defects
in angiogenesis and vasculogenesis.38 Accordingly, over
expression of FAK in vascular endothelial cells promotes
angiogenesis.39 In addition, conditional deletion of FAK
in adult mouse epithelium was not lethal, and probably
due to a functional compensatory effect mediated by its
related family member PYK2.40 Although PYK2 knock out
mice develop normally except they do exhibit defective
macrophage migration.41,42 The above data suggested that
endothelial cells may posses an adaptive capacity to switch
to PYK2 dependant signaling after deletion or inhibition
of FAK. Thus, FAK and PYK2 inhibition may result in an
antiangiogenic effect.
An interesting interaction has also been reported between
FAK and the tumor suppressor protein p53, via the FERM
domain that triggers p53 degradation, so that loss of FAK
results in activation of p53 which could eventually suggest new
approaches to trigger cytotoxic drug induced apoptosis.43
Although, Src-null mice were viable, the analysis of
homozygous mutants showed that they were deficient in
bone remodeling (they had an impaired osteoclast function)
and also developed osteopetrosis. This phenotype demonstrated that Src is not required for general cell viability
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possibly due to a Src functional overlap with other related
tyrosine kinases such as FAK. Therefore, Src may play
an essential role in bone formation.44 Accordingly, cancer
patients treated with a Src inhibitor showed reduced serum
levels of bone resorption markers suggesting Src inhibitors as a possible effective treatment for established bone
metastasis.45,46
In normal adult tissues and tumor cells, FAK and Src
control many important biological processes within the cell.
They have been associated with responses of cell growth
and survival.9,10 In addition, they have also been involved
in anoikis (apoptosis induced when anchorage-dependent
cells detach from the surrounding ECM) resistance in
tumor cells.47–50 Hence, FAK/Src activation may promote
the anchorage-independent growth/transformation of tumor
cells through the inhibition of the apoptotic response.48,49
FAK activation, in response to integrins, has an important
role in FA turnover/rearrangement. This process is crucial
for cell spreading and migration in physiological and
pathological processes (ie, FA turnover is essential for
EMTs during the metastatic behavior of tumor cells and
in endothelial cell migration during tumor angiogenesis).9
Phosphorylation of FAK-Y925 is the major Src-specific
phosphorylation event that is associated with integrin
adhesion dynamics and E-cadherin deregulation during
Src-induced EMT.29,30
Furthermore, FAK has already been found, at elevated
levels, in the majority of human cancers (head and neck,
colon, breast, prostate, liver, thyroid, and others), particularly
in highly invasive metastases.51 High levels of Phospho-FAK
Y397 has already been found in: ovarian invasive tumors;52
acute myeloid leukemia;53 squamous cell carcinoma of the
laryn;54 invasive cervical carcinoma;55 invasive human colon
cancer cells;56 medullary thyroid cancer cell lines;57,58 human
pancreatic cancer cells;59 glioma cells;60 and other tumor
types. Furthermore, high levels of FAK phosphorylated in
other tyrosine residues have already been found in specific
tumor types. Papillary thyroid cancer samples show high phosphor-Y861-FAK levels and high levels of phopho-Y861-FAK
have also been correlated with sensitivity to the Src inhibitor
AZD0530 in papillary and also in anaplastic thyroid cancer
models.61 Although, the relationship between Src and cancer
progression is best documented in colon and breast cancer.10,62
Src over expression or over activation has also been shown in
a variety of human biopsies from primary tumors and their
metastases (Figure 3).23
An additional pro-angiogenic role for FAK and Src
signaling in tumors has also been suggested.63–69 FAK
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expression has been found in tumor endothelial cells
from grade III and IV astrocytoma biopsies; whereas FAK
expression was absent in endothelial cells of normal brain
biopsies.63 Accordingly, tumor endothelial cells transfected
with FRNK (a negative FAK regulator) showed less
migration in vitro than control cells; suggesting that FAK is
involved in tumor-angiogenesis, at least in part, through the
induction of endothelial cell migration.63 Preclinical data
from prostate cancer cell lines have also suggested a role
for FAK signaling in the induction of VEGF expression
in tumor cells.70 Additionally, an intracellular cross-talk
between the Ang-1 TKR (Tie-2) involved in angiogenesis
in tumors and integrin pathways has also been shown.71
The binding of integrin α1β5 to ECM-glycoproteins may
lead to the association of Tie-2 with integrin α1β. The
stimulation of Tie-2 by Ang-1 may promote the recruitment
of FAK to the TKR-integrin areas inducing an endothelial
cell response (sprouting and stabilization of the new tumor
vessels).71 Src has also been associated with VEGF production in tumor cells.66 In fact, Src inhibition decreases
angiogenesis in vivo.68,69

Immunohistological data about the expression/correlation between active FAK/Src on primary tumors and on their
metastases is still awaited, to explore the value of FAK/Src
as predictors of tumor outcome.
In fact, as we will review below, a link for FAK/Src
with chemoresistance has already been reported in tumor
models. In fact, FAK downregulation enhances docetaxel
cytotoxicity in ovarian cancer cells. 72 Moreover, FAK
downregulation also increases gemcitabine chemosensitivity in pancreatic cancer cells.73 Accordingly, a variety
of reports show a role for Src in the promotion of chemoresistance.74–77 Src inhibitors have already shown single
agent activity in cancer patients after their progression to
chemotherapy.78 Src inhibition promotes chemosensitivity
in pancreatic cancer cells.74 In addition, a combination of
5-fluorouracil (5-FU) and a Src inhibitor in 5-FU-resistant
human pancreatic cancer cell lines restored 5-FU-induced
apoptosis.74 The potential mechanism for 5-FU chemosensitivity induced by Src inhibitors might be associated with
the inhibition of the epidermal growth factor receptor-AKT
(EGFR–AKT) pro-survival pathway induced by 5-FU. Fur-

Solid tumor progresion
Normal epithelium

Dysplasia/Adenoma

Carcinoma in situ

EMT

Invasive
carcinoma

Basement membrane
ECM

Local invasion

FAK and Src
overexpression/overactivation

Figure 3 Role of the FAK-Src complex in the malignant progression of solid tumors.
Notes: FAK and Src play a critical role in solid tumor progression mainly through its ability to promote the epithelial-mesenchymal transition associated with the metastatic
behavior of solid tumors.
Abbreviations: ECM, extracellular matrix; EMT, epithelial mesenchynal transitions; FAK, focal adhesion kinase; Src, steroid receptor coactivator.
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thermore, a role for Src in mediating acquired endocrine
resistance is also well established.10
Other FAK family members have also been associated
with cancer. In fact, Pyk2 also shows a high expression
and an association with tumor progression in a variety of
tumor types such as: astrocytomas; breast; glioma; prostate;
hepatocarcinoma; and nonsmall cell lung cancer.79–83 In
addition, other Src family members have also been associated
with solid and hematological tumors; and inhibitors against
Src family members are under development as new anticancer
drugs.84

FAK-Src and tumor associated
epithelial mesenchymal transition
Epithelial mesenchymal transition (EMT) is a complex of
cellular and molecular processes by which epithelial cells
acquire mesenchymal and migratory properties.85 EMT takes
place during critical phases of embryonic development and
is also a crucial step in the infiltration and progression in
solid tumors. Hallmarks of EMT include loss of cell–cell
contacts, induction of FA turnover and increased expression
of mesenchymal (f ibronectin, vimentin, N-cadherin,
α-smooth muscle actin, and others) and invasiveness
(ie, metalloproteinases) markers.86 The EMT is at the
convergence of different molecular pathways involving cell
survival and resistance to apoptosis, invasion and tumor
angiogenesis, metastasis and drug resistance in advanced
tumors.87
A critical molecular feature in the loss of cell–cell
contacts during EMT is the downregulation of the adhesion
molecule E-cadherin (delocalization/loss of E-cadherin
expression). A variety of membrane receptors such as
integrins, TKRs, serine-threonine kinase receptors are able
to induce E-cadherin downregulation during development
and tumor progression through the activation of specific
intracellular signaling cascades such as Ras-MAPK and
PI3K-Akt-mTOR. In fact, transcriptional repressors
(Snail, Slug, Twist, or ZEB1/2) involved in EMTs during
development are also induced in response to EMT stimuli
to repress E-cadherin expression during tumor progression.86 Plenty of evidence suggests that FAK and Src,
through its ability to integrate signals from numerous signaling receptors, plays a critical role in tumor-associated
EMTs promoting intracellular signaling pathways that
lead to the induction of E-cadherin repressors and to the
subsequent E-cadherin downregulation as well as that promote FA turnover to allow tumor cell migration/invasion
(Figure 1B).88–91
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New anticancer drugs that
target FAK and Src
Based on evidence that supports FAK as a molecular scaffold
protein, activated by Src to recruit its substrates; and that Src, as
a tyrosine kinase is involved in the catalytic activation of FAK,
and triggers FAK kinase activity to promote a variety of cellular
responses during tumor progression, preclinical and clinical
studies with new agents that employ different mechanisms for
the blockade of FAK or Src kinases are currently underway.9,10
We show below a summary of the most advanced FAK and
Src inhibitors under development (see Table 1).
Historically the first drugs synthesized with the aim of
inhibiting T-cell activation via the Src family kinases Lck and
Fyn were PP1 and PP2. The latest one is very selective for
Src family kinases (SFKs). After PD173955 and PD173956
emerged with a lower selectivity than that of PP2, since these
compounds were inhibitors of; Abl, Csk, platelet derived
growth factor receptor (PDGFR) and EGFR. CGP76030
and CGP77675 were also multi-targeted agents against
SFKs, Abl, EGFR and VEGF receptor (VEGFR) and SFKs,
EGFR, FAK, and VEGFR, respectively. A third generation of
molecules characterized by their higher potency in enzyme
assays and their dual inhibition of c-Abl in a variety of imatinib-resistant c-Abl mutations appeared. The strong activity
against c-Abl together with the potent anti-Src activity is
explained by the strong structural similarity of the ATP binding domains in both kinases. The dual selectivity speeded up
the development of these compounds.
At present, researchers are strongly focused on the
study of the potential therapeutic benefits from the use of
ATP-competitive kinase inhibitors against FAK and Src.
These inhibitors interact with the ATP-binding pocket
of FAK or Src and subsequently prevent FAK and Src
autophosphorylation and therefore their activation.11

Dasatinib
Dasatinib (BMS-354825) is an orally active small multiselective
inhibitor, which inhibits the kinases Src and Abl with IC50 values of 0.55 and 3.0 nM, respectively.92 Dasatinib also inhibits
other Src family members such as Fyn (half maximal inhibitory
concentration [IC50] of 0.2 nM), LcK (IC50 of 1.1 nM) and
Yes (IC50 of 0.4 nM).92 Dasatinib blocks the wild type chimeric
Bcr-Abl protein which arise from Philadelphia chromosome.93
Dasatinib is a 20-fold more potent inhibitor than imatinib
in cells expressing wild-type Bcr–Abl hybrid protein and it
also has an antitumoral effect in those tumor cells expressing Bcr–Abl imatinib-resistant mutants.93 Dasatinib is also
able to inhibit the tyrosine kinase receptors c-KIT, PDGFR-β

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

89

Dovepress

Bolós et al

Table 1 Summary of FAK and Src inhibitors under clinical and preclinical development
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Drug

Target
(IC50)

IC50

IC50

IC50

Src

FAK

Abl

IGF1R

BMS-354825
(Dasatinib)

0.55 nM

PF-562,271

797 nM

TAE-226
AZD0530

3.0 nM

1.5 nM
(0.7 ng/mL)

500 nM

100 nM/L
= 100 nM

300 nM/L
= 300 nM

4 nM
27 nM
3.8 nM

SKI-606
(Bosutinib)

Clinical activity

Solid and hematological
tumor models

Approved in Imatinib
r efractory CML and
Philadelphia chromosome + ALL,
Phase 1–2 clinical trials in
solid and hematological tumors
are underway
Phase 1 clinical trial in solid
tumors has been already
communicated
Not yet

Colon, breast, prostate,
pancreatic and lung tumor
models
Glioma and human
pancreatic tumor cell lines
Skin, prostate, breast
and pancreatic tumor models
CML, colon and breast models

Phase 1–2 clinical trial
underway
Phase 1 clinical trial has been
already communicated, Ph II
clinical trial in CML patients
after imatinib failure under
development

Abbreviations: FAK, focal adhesion kinase; CML, chronic myelogenous leukemia; IGF, insulin-like growth factor; IC, inhibitory concentration.

and ephrins (EPHA2).92 Dasatinib has already shown to have
broad preclinical activity in solid and hematological tumor
models.14,92 It has already been approved by the Food and Drug
Administration (FDA) and by the European Medicines Agency
(EMEA) for the second line treatment of imatinib-refractory
chronic myelogenous leukemia (CML) and Philadelphia
chromosome-positive acute lymphoblastic leukemia (ALL).14
Currently, phase I/II clinical trials with dasatinib as a single
agent or in combination are underway in a variety of solid and
hematological tumors, based on the capability of dasatinib for
blocking the activity Src family members.94 Besides effectiveness in hematologic malignancies, dasatinib can suppress
tumor growth in human breast cancer, human prostate, colon,
ovarian, and lung cancer lines.95–100

AZD0530
AZD0530 is another novel, orally administered, potent,
and highly selective inhibitor of Src (IC50 value  4 nM),
other Src family members like LcK and Yes (both with
IC50 values  4 nM) and Abl as well.101 Preclinical activity
has been shown in: skin; breast; prostate; and pancreatic
tumor models101 as well as estrogen receptor-positive breast
cancer models102 where the combination of AZD0530 with
tamoxifen103 and aromatase inhibitors104 prevented hormonal
therapy resistance. This combination also shows an additive
effect of delaying the growth of breast cancer cells.105
A variety of phase I and II clinical trials are currently
underway with AZD0530 in monotherapy or in combina-
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tion, in patients with solid tumors based on its capability to
inhibit Src.106 Another possible use of AZD0530 has been
recently reported. Based upon the hypothesis that Src could
be involved in the development of metastases in xenograft
modes where the growth of the primary tumor was controlled
by radiation; this report shows that those tumors from mice
receiving AZD0530 regress more quickly following radiotherapy than their control counterparts.107

Bosutinib
Bosutinib (SKI-606) is a potent, orally administered,
bioavailable, dual Src (IC50 value of 3.8 nM) and Abl inhibitor
which has already shown to have an antitumoral effect in
chronic myelocytic leukemia (CML), colon, prostate and
breast cancer models.108,109 Preclinical breast cancer models
showed a decrease in in vitro cell motility and invasion and
in vivo metastases after bosutinib treatment.110 A phase I
clinical trial with bosutinib has been published showing; drugrelated dose-limiting toxicity of grade 3 diarrhea and grade
3 rash (1 pt) with 400 mg being selected as the maximum
tolerated dose.111 Currently, phase II, proof of concept clinical
trials, in patients with CML who had failed to improve with
Imatinib, and in patients with solid tumors, are underway.112

PF-562,271
PF-562,271 is a potent ATP-competitive, small molecule
inhibitor of both FAK and the related kinase Pyk2 (IC50 values
of 1.5 nM (0.7 ng/mL) and 14 nM (7 ng/mL), respectively).
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PF-00562271 also inhibits other kinases such as c-Src and
insulin growth factor 1 receptor (IGF1R) with less selectivity
(IC50 value of 797 nM and IC50  500 nM respectively).
This inhibitor has shown a broad preclinical activity.113 In
PC3 human prostate tumor cells, PF-00562271 treatment
blocks, anchorage independent tumor cell growth and tumor
cell migration in vitro, has shown antitumoral effects in vivo.11
PF-00562271 decreases FAK phosphorylation-status in vitro
and shows antitumor efficacy in vivo, in xenografts from:
human colon; breast; prostate; pancreatic; and hepatocellular
carcinoma tumor cell lines.113–115 No weight loss, or increase in
morbidity and mortality were observed in any in vivo experiment and tumor growth inhibition was dose and drug exposure
dependent. Furthermore, PF-562271 also showed an additional
antiangiogenic effect over tumors.113 PF-562271 through the
inhibition of FAK and PYK2 kinases may interfere with the
ability of endothelial tumor cells to migrate, thus blocking
the sprouting and stabilization of the new tumor vessels.63,116
PF-00562271 treatment has also led to the blockade of the
expression of pro-angiogenic growth factors in tumor cells,
such as VEGF.70 Recently, Bagi and colleagues showed that
PF-00562271 synergized with antiangiogenic agents that
directly block VEGF signaling, through its ability to target
different aspects of angiogenesis and tumor aggressiveness.115
In addition, these authors show that the combination of these
agents not only led to the blockade of tumor growth, it also
impacted upon the ability of the tumor to recover on withdrawal
of the therapy. PF-562,271 has also showed an in vivo effect
in preventing the loss of bone, suggesting its potential activity in patients with bone metastases and cancer-associated
osteoporosis.117 Therefore, PF-562,271 may comprise of a
combined action over tumors: antiproliferative; proapoptotic;
antiangiogenic; and antimetastatic action. Based on the
preclinical data, a dose escalation phase 1 clinical trial with
PF-562,271, administered orally as a single agent, in patients
with solid tumors is currently underway. Tumor responses
with PF-562,271 have been already reached in ovarian, colon
together with head and neck cancer patients. Preliminary
results showed a manageable safety profile with PF-562,271.
In addition, continuous oral dosing is feasible and may be
extended over 6 to 12 months in the majority of patients. The
most common adverse events in the 32 evaluated patients with
monitored safety data was: nausea in 14 patients (Grade 3);
vomiting in 12 patients (only 1 patient with Grade 3); fatigue
in 8 patients (Grade 3); and diarrhea in 6 patients (Grade
3). Prolonged disease stabilization has already been observed
in a variety of solid tumors. However, the maximum tolerated
dose (MTD) and recommended Phase 2 dose have still to be
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published.15,16 In addition to PF 573,228, a closely related, early
prototype FAK inhibitor118 has been reported to have appealing
activity in combating ovarian cancer metastases,119,120 demonstrating the growing body of evidence that supporting research
of Src/FAK inhibitors in epithelial carcinoma.

TAE 226
TAE 226 is a low molecular weight, ATP-competitive tyrosine kinase inhibitor of FAK and IGF1R with an IC50 range
of 100 to 300 nM/L.121 TAE 226 is still under preclinical
development. Flow cytometry analysis of human glioma cell
lines under TAE 226 treatment have shown an increase in
the apoptotic and G0 (quiescent/nonproliferative) fractions
after treatment, when these cells were compared with control/
nontreated cells.60 TAE 226 induced-apoptosis in the glioma
tumor model is mediated by caspases and is correlated with
the p53 status. In fact, apoptosis was only induced in the subset
of glioma cell lines containing the mutant p53 gene.60
Additionally, TAE 226 treatment also prevented the in vitro
attachment of these glioma cell lines. Furthermore, an in vivo
intracranial glioma xenograft model showed a significantly
higher median survival in the group of mice treated with
TAE 226, at concentrations of 50–75 mg/kg. The treatment of
ovarian cancer cell lines with TAE 226 inhibited cell growth
in both a time- and dose-dependent manner; and enhanced
docetaxel-mediated growth inhibition by 10 and 20 fold in the
taxane-sensitive and taxane-resistant ovarian cell lines, respectively. In addition, TAE 226 alone and in combination with
chemotherapy significantly prolonged survival in tumor-bearing
mice. The efficacy of TAE 226 was related to: reduced pericyte coverage; the induction of apoptosis of tumor-associated
endothelial cells; reduced microvessel density and tumor cell
proliferation.121 TAE 226 also displayed an antitumoral effect
in human pancreatic cell lines,122 esophageal cancer cell lines
and xenografts, by a potent inhibition of PI3K-AKT-mTOR cell
survival signaling.123 Clinical trials with this new dual FAKIGF1R inhibitor are planned. Recently, interesting experiments
have suggested that the FAK–IGF–1R interaction site could be
targeted; the specific disruption of this protein–protein interaction with another small molecule inhibitor (INT2-31) reinforces
the potential novel role of this antineoplastic strategy.124

FAK/Src and chemotherapy
resistance
As we mentioned above, an association between FAK
activation and resistance to chemotherapy has been broadly
reported in human tumor models.72,73,125–128 Accordingly, the
combination of conventional chemotherapeutic drugs with
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FAK-targeting agents apparently offers greater efficacy in
preclinical models than chemotherapy as a single agent.
Treatment with FAK antisense oligonucleotides significantly
induced apoptosis in human glioblastoma cells associated
with a decrease in FAK protein levels.129 The in vitro cytotoxic
effect achieved with the anti-FAK agent in monotherapy
was almost the same as those obtained with different
chemotherapeutic regimens such as cisplatin, etoposide
and nimustine hydrochloride. 129 When FAK antisense
oligonucleotides and chemotherapy were administered in
combination the antitumoral effect was clearly additive.129
Treatment of squamous cell carcinoma models with recombinant FRNK peptides combined with etoposide, paclitaxel
or 5-FU also showed an additive antitumoral effect.127
The effect of combined chemotherapy and anti-FAK agents
were also explored in human HCC cells in vitro.130 When TNFα plus cycloheximide was combined with FAK-antisense, an
increase in the apoptotic index was observed.130 Additionally,
FAK siRNA was also able to potentiate gemcitabine action
in pancreatic cancer cells73 increasing the apoptotic index.
The in vivo treatment with FAK siRNA, in combination with
gemcitabine, induced in a statistically significant manner, a
larger inhibition in the size of the tumors than gemcitabine
in monotherapy.73 FAK siRNA incorporated in liposomes
was administered to mice bearing tumors from human ovarian cancer cells.131 Mice treated with siRNA-DOPC showed
a decrease in tumor weight. Docetaxel in combination with
siRNA-DOPC resulted in an even greater reduction in tumor
weight.131 This combination also showed: antiangiogenic
properties;131 it decreased microvessel density; VEGF and
MMP-9 secretion; and increased apoptosis in tumor cells, in
addition to tumor-associated endothelial cells.131 Treatment
with siRNA-DOPC resulted in a decrease in the tumor weight
of cisplatin-resistant xenografts as well.131 These data suggest that the combination of anti-FAK agents with docetaxel
or cisplatin may be a valuable therapeutic approach in the
chemotherapy of resistant ovarian cancer. Smith and colleagues
showed that FAK downregulation enhanced the effects of 5-FU
in human melanoma cells.132 FAK antisense oligonucleotides
significantly increased cell detachment and apoptosis when
they were administered alone or in combination with 5 FU.132
This led to the decrease in FAK protein levels, an effect that
was also observed with the 5-FU alone. Accordingly, FAK
blockade plus 5-FU showed and additive effect.
There are also, preclinical data supporting the role of
Src in chemoresistance. The inhibition of Src reversed
chemoresistance toward 5-FU in human pancreatic carcinoma
cells.74 Furthermore, Src inhibition also impaired both inherent
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and acquired gemcitabine resistance in human pancreatic
adenocarcinoma cells.75 The combination of dasatinib and
chemotherapy (5′-5′-DFUR or cisplatin) was synergistic in
triple-negative breast cancer cells.99 In addition, phase 1 clinical trials are currently ongoing, with the Src inhibitor dasatinib
in combination with chemotherapy in solid tumors.94,133
Interestingly the combination of paclitaxel/carbolatin
standard chemotherapy in ovarian cancer has shown
interesting synergism from this combined approach at the
cell line level, that requires further investigation.134
In conclusion, current evidence shows that FAK/
Src-targeting compounds enhance the action of conventional
anticancer agents at least in preclinical tumor models.
Nonetheless, further molecular studies testing the activation
status of both kinases in tumor biopsies and clinical trials,
with anti-FAK/anti-Src agents and different chemotherapeutic
schedules are still required to confirm if this complex is
involved in treatment resistance and if the combination can
enhance the efficacy of conventional chemotherapy in the
clinical setting.

The interest of targeting FAK
and Src in breast cancer
The Src/FAK signaling pathway is related to multiple receptor
tyrosine kinases (RTKs) and intracellular mediators with a
prominent role in the biology of the different subtypes of
breast cancer.135
On one hand, c-Src interacts with and contributes to the
signaling cascade of different RTKs; modulates their turnover
by interfering in the endocytosis; and ubiquitination; in to
taking part in the cytoskeleton rearrangement, migration and
survival processes started at the RTKs’ level in tumor cells.7
In breast cancer there is evidence of the interaction between
c-Src and EGFR, (although short of a synergistic activity),
connected to the crosstalk between estrogen receptor (ER)
and EGFR.136,137 HER2 is coexpressed with c-Src in breast
cancer138 and their interaction seems to facilitate the migratory
and metastatic phenotype of these cells.139,140 Likewise, HER2
is actually involved in c-Src regulation,140 another mechanism
of activation of HER2 such as the transactivation through
G-protein receptors (ie, CXCR4).141 C-Src has also been
proposed to be involved in the modulation of HER2–HER3
heterocomplexes in an intracellular mediated pattern.142
However, Src has also been linked to the endoplasmic
reticulum (ER) nongenomic activity143 and the homeostasis
of the ER144 in the tumor cells.
Src inhibitors have been developed in different breast
cancer subtypes. Triple negative breast cancer has emerged
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as a potential field to be explored by this family of drugs.
Two independent groups have described genetic profiles
associated with a response to dasatinib95,145 highlighting
the particular sensitivity of the basal-like phenotype to
this Src inhibitor. This molecular marker approach has led
to a phase 2 trial in the clinical setting146 showing modest,
although encouraging, results to be tested in further trials,
in combination with chemotherapy.
Hormone receptor-positive breast cancer, resistant to the
classic endocrine therapy strategies, has become another
field actively studied. In the tamoxifen resistance setting, the
upregulation of different RTKs’ signaling pathways has been
involved. It has been suggested that the resistant phenotype
is not just the result of an estrogen independent growth,147
but is also linked to an alteration in the relationship between
the cells and the extracellular matrix, so that these tumor
cells acquire an invasive and migratory phenotype148,102 that
favors tumor dissemination. It has been demonstrated that
anti-HER2 therapies are able to eliminate the agonist effect
of tamoxifen, restoring its antitumoral capacity149 and the
blockade of both pathways, showing an increased efficacy
against endocrine-resistant tumors.100,150,151
However, these combinations have not shown a definitive
effect regarding the migratory and invasive phenotype,148
moreover, the tumoral cells eventually develop double
resistance that results in an even more invasive behavioral pattern.102,152 This dual resistant phenotype is characterized by an
increase Src kinase activity, that defines another opportunity
to target endocrine resistant breast cancer. The in vitro utility
of Src inhibitors; due to the Src/FAK relationship in the acquisition of endocrine resistance in breast cancer, has already
been tested.153–156 However, a recent article showed an opposite role for Src in breast cancer. Campbell and colleagues
analyzed 262 breast cancer specimens, before tamoxifen
treatment, for active Src expression by tissue microarray.
The authors showed that phosphorylated c-Src in the nucleus
was significantly associated with improved patient outcome
in ER-positive breast cancer.157 The current findings suggest
a crosstalk between ER and Src/FAK kinases, so that the addition of agents that block Src and/or FAK to hormonal therapy
may improve the efficacy of the current endocrine therapies
(aromatase inhibitors and tamoxifen). Clinical trials in breast
cancer patients with dasatinib and aromatase inhibitors are
underway in breast cancer patients.94

of convergence in the signaling initiated by a variety of
membrane receptors (RTKs, Integrins, G-coupled receptors, ER and others) to trigger a cascade of phosphorylation
events and new protein–protein interactions in tumor cells
and tumor endothelial cells, that allow the angiogenic and
metastatic behavior of tumors. In fact, preclinical data
with anti-Src and anti-FAK agents under development
show that both types of inhibitors lead to antiproliferative,
antiangiogenic and antimetastatic responses in human
tumor models; a synergistic effect with other anticancer
agents has been also observed. Therefore the inhibition
of one of these kinases appears to be a successful therapeutic approach to avoid recurrence and dissemination of
the primary tumor and also the progression of metastatic
lesions.
Currently, we have robust data to believe FAK and c-Src
inhibitors as a novel and promising anticancer strategy to
combine with current anticancer therapies. A synergistic
effect has already been shown when they are combined
with other antitarget agents (ie, gefitinib, imatinib and
sunitinib). Furthermore, these drugs have also been shown
to be good candidates in the avoidance of chemotherapy and
hormonotherapy resistances.
In addition, although it remains difficult to asses the
efficacy of antimetastatic agents in the clinical setting,
its appears that the inhibition of Src and FAK may have a
potent anti-invasive effect, to delay tumor dissemination
rather than real tumor shrinkage. Furthermore, although
levels have already been seen as a possible predictor of
response to Src inhibitors there is still a lack of suitable
biomarkers that would be able to predict a response to these
agents. In addition to current clinical studies of biomarker
assays, the use of more sophisticated imaging technologies and the testing of the tumor, guided by biochemical
rational, will help to maximize the development of these
new compounds.
We have reviewed those trials with FAK and Src inhibitors
under clinical development as a single agent or in combination with other therapeutic approaches. They have already
shown clinical benefits in cancer patients with solid tumors.
The identification of useful biomarkers to assess target inhibition, anti-invasive efficacy and predict treatment response
will be crucial for future clinical trials.

Conclusions
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As we reviewed above FAK and Src form a mutually
activated complex that acts as a common intracellular point
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